Oncology

An integrated strategy can simplify the development of antibody-drug conjugates.

Less manufacturing time could be the difference between a patient receiving this life-saving therapy vs not.

Decentralized clinical trials are emerging as a method by which to address gender bias in clinical research.

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

The immune checkpoint inhibitor increased inflammation within the tumor, which may be linked to better response to nivolumab treatment.

pCR rates improve regardless of whether patients received full chemotherapy doses.

Providers can consider the patient’s medication history, comorbidities, or migraine type to help choose a first line treatment or refer the patient to specialized care.

Trastuzumab deruxtecan and elacestrant represent important new treatment options.

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

No established standard of care currently exists after spread to the lymph nodes.

Please take 10 minutes to complete the 2024 Burnout and Mental Health Survey.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

Older patients’ underrepresentation in clinical trials leaves a gap in data regarding appropriate treatment.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.

The combination resulted in numerically longer OS compared with an NSAI alone.

The candidate has already demonstrated anti-tumor activity in chemotherapy-naïve patients.

A risk-stratification screening approach that considers screening at an earlier age based on risk factors might increase the likelihood of catching the cancer before it turns symptomatic.

The MRD-guided treatment approach has a significant advantage over chemotherapy.

Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.

A recent study sheds light on an alarming number of hormone-disrupting chemicals that are found in everyday settings.

It can also help identify patients who would benefit from disease-specific therapies.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

This RNA type might act as an onco-suppressor, and higher levels may indicate better prognosis.

Berberine was associated with a reduction in inflammatory markers in the lungs, which was caused by the colorectal cancer.

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

The third edition of the Pharmacy Quality Alliance resource guide includes 40 total SDOH services and 8 new services, as well as 10 initiative updates from the previous 2 editions.

Further policy changes to promote gender equity may be needed.

The treatment is for patients with KRAS G12C-mutant metastatic NSCLC who have previously received at least 1 systemic therapy and were not treated with a KRAS G12C inhibitor.

Ph-like ALL may be predominantly prevalent in Hispanic and Latino populations.